D-Index & Metrics Best Publications

Richard A. Larson

University of Chicago
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 153 Citations 114,104 990 World Ranking 540 National Ranking 324

Overview

What is he best known for?

The fields of study Richard A. Larson is best known for:

Cancer
Gene
Chemotherapy

His biological study deals with issues like Animal science, which deal with fields such as Hay and Herd. His research brings together the fields of Animal science and Herd. His study looks at the intersection of Pipeline transport and topics like Mechanical engineering with Pipeline (software). Complete remission and CHOP are the two main areas of interest in his Chemotherapy studies. Richard A. Larson connects CHOP with Chemotherapy in his study. He links relevant research areas such as Pipeline (software) and Transient (computer programming) in the realm of Operating system. Transient (computer programming) is closely attributed to Operating system in his study. Richard A. Larson integrates Genetics and Computational biology in his studies. In his works, he performs multidisciplinary study on Computational biology and Gene.

His most cited work include:

East Pacific Rise: Hot Springs and Geophysical Experiments (657 citations)
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma (516 citations)
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity (387 citations)

What are the main themes of his work throughout his whole career to date

His Internal medicine study frequently draws parallels with other fields, such as Myeloid leukemia. His study ties his expertise on Chemotherapy together with the subject of Genetics. His Chemotherapy study frequently draws connections between adjacent fields such as Genetics. His study deals with a combination of Gene and Biochemistry. He connects Biochemistry with Gene in his research. Leukemia is closely attributed to Immunology in his work. His study ties his expertise on Leukemia together with the subject of Immunology. In his works, Richard A. Larson undertakes multidisciplinary study on Oncology and Cancer research. He performs multidisciplinary studies into Cancer research and Oncology in his work.

Richard A. Larson most often published in these fields:

Internal medicine (38.10%)
Genetics (25.40%)
Gene (22.22%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4398 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

4139 Citations

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Blood (2017)

4082 Citations

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)

3927 Citations

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Blood (2010)

3795 Citations

The antioxidants of higher plants

Richard A. Larson.
Phytochemistry (1988)

2337 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2302 Citations

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Blood (2002)

2224 Citations

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith.
Journal of Clinical Oncology (2002)

2085 Citations

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne.
The New England Journal of Medicine (2010)

1942 Citations

If you think any of the details on this page are incorrect, let us know.